Nicolas Quesnot

Senior Scientist - Preclinical Safety Debiopharm

Nicolas is Senior Scientist in Non-Clinical Safety at Debiopharm with over 10 years of industry experience across preclinical toxicology and safety pharmacology, having been with the company for four years after building his expertise at CROs and mid-sized pharma. In this role, he contributes to translating preclinical discoveries into clinical strategies, supporting the development of ADC therapies. Holding a Ph.D. in Toxicology from the University of Rennes, France and a DIU in Immunology and Biotherapies from Paris Sorbonne University, he is passionate about leveraging NAMs to advance modern toxicology and innovative therapies for unmet needs in oncology.

Seminars

Monday 8th March 2027
Enlarging the Therapeutic Window: A Novel Stepwise-Cleavage Linker for Next-Generation MMAE ADCs
11:30 am
  • Discovering a novel linker technology to broaden the therapeutic window for MMAE-based ADCs, tackling the long-standing challenge of pairing this highly potent payload with an acceptable safety margin
  • Comparing data against traditional MMAE linker chemistries, benchmarking efficacy and toxicity outcomes across pipeline
  • Uncovering early progress toward dual-payload format, unlocking toxicity margin associated to combination with traditional ADC payloads 
Nicolas Quesnot - Debiopharm